Navigation Links
Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine

HybSelect(TM) first to provide high coverage and megabase capacity for the next generation sequencing community

LEXINGTON, Mass. and HEIDELBERG, Germany, March 16 /PRNewswire/ -- febit today announced the official launch of its new sequence capture technology HybSelect. In several biomedical studies of early access customers over the past months, HybSelect demonstrated superb enrichment factors and deep sequencing coverage for a broad range of human genes and genomic regions. As the first sequence capture technology combining outstanding enrichment and walk-away convenience, HybSelect opens up new opportunities in biomarker discovery and the development of personalized medicine.

Declining costs and dramatically higher sequencing output has distinguished the fast-paced genomics market since 2003. Sequencing a human genome, a project that required years and billions of USD, is now feasible in weeks for thousands of USD. Nevertheless, conducting statistically relevant biomedical studies with deep sequencing of patient samples is still prohibitively expensive and inefficient. HybSelect effectively scales next generation sequencing to the needs of biomedical research and discovery by enabling large scale studies.

The accessibility and enormous capacity of the next generation sequencers have triggered a heightened demand for sequence capture technologies amongst geneticists: targeted re-sequencing of medically-relevant genome loci will greatly enhance the understanding of health and disease in crucial areas such as cancer and Alzheimer's disease. The outcomes of such studies are significant in that they will allow improved diagnostics and targeted applications of medical agents.

"HybSelect even enables large scale targeted re-sequencing studies because of the high degree of automation combined with the power to detect genetically relevant information in the genome with high efficiency, which can not be met by PCR, or other methods on the market. The fully automated HybSelect technology will compel adoption in several ways: short hands-on time (minutes instead of hours), a high degree of reproducibility, and unmatched parallelism in hybselecting several genomic samples at a time," said Peer Staehler, CSO of febit, summarizing the advances of febit's latest product.

The proof of concept has been positively confirmed by early access customers. Dr. Matthew Huentelman, an investigator and lead collaborator at the Translational Genomics Research Institute (TGen) in Phoenix, AZ, was one of the first researchers to use HybSelect. His laboratory uses state-of-the-art techniques to pin-point differences in genes and pathways that contribute to the development and progression of Alzheimer's disease. "We are really excited about the high enrichment factor and the depth of coverage of the targeted sequences that can be achieved using HybSelect from febit. The short hands-on time and ease of use reinforce our intentions to use this new technology for further studies," said Dr. Huentelman.

HybSelect will be also employed in the newly developed Biomarker Discovery Center Heidelberg for the detection of novel tumor markers. Within the European READNA-consortium (REvolutionary Approaches and Devices for Nucleic Acid analysis) HybSelect will support the selection and enrichment of specific gene loci for Next Generation Sequencers.

The new technology is available as a protocol for febit's Geniom RT Analyzer, or as a full service including Next-Gen sequencing from febit. HybSelect is optimized for the Illumina GAII sequencing system, and will be available for other sequencing platforms soon.

HybSelect will be presented at CHI's Conference on Next-Generation Sequencing on March 17-19, 2009 in San Diego, CA. To learn more about febit's new HybSelect technology the febit product launch offers a webinar on March 25, 2009 (11:00 am EDT, 4:00 pm CET).

About febit

febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit's product portfolio includes various instruments, optimized assays, and bioanalytical services, complemented by bioinformatics software and consulting.

For its main applications, HybSelect -- febit's innovative DNA capture method for Next-Generation-Sequencing -- and protein-coding or non-coding transcriptome profiling, the highly advanced microfluidics of the patented Geniom Biochip offers the highest degree of automation, flexibility and efficiency available.

For more information please visit:

            Contact: febit group, Eva Sterzel,,
                                +49 (0)6221 6510-300
                        Russo Partners, Martina Schwarzkopf,
  , +1 212 845-4292

SOURCE febit
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling
2. T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture
3. Xceed Ziplex(R) System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award
4. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
5. Animetrics Inc. Selected to Provide 3D Face Viewer Technology for United States Army Biometric Automated Toolset (BAT)
6. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
7. Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16
8. Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution
9. diaDexus Selects Fisher HealthCare to Sell New Automated PLAC(R) Test
10. Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell
11. Microfluidic Systems to Show Automated Biological Agent Detection Technology to U.S. House of Representatives
Post Your Comments:
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks Associates ... will speak at the TMA 2017 Annual Meeting , October 11 ... in the residential home security market and how smart safety and security ... Parks Associates: ... "The residential security ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at . 2016 ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
Breaking Biology News(10 mins):